10x Genomics
TXG · NASDAQ · Healthcare
$75.62
$3.33 (-4.40%) today
Market Cap
$2.20B
24h Volume
$262.6M
P/E Ratio
-9.2
52w High
$79.10
52w Low
$11.34
Est. AI Revenue
15%
7-Day Sparkline (Static)
Company facts
Performance
About 10x Genomics
10x Genomics is a life sciences tools company. It sells instruments and consumables for single-cell and spatial biology, which let researchers study biological systems cell by cell. Revenue comes from instrument placements and the recurring consumables those instruments use.
AI powers the analysis side of its platforms. Products include Chromium for single-cell analysis, Visium for spatial biology, Xenium with AI-driven analysis, and the Cell Ranger software pipeline. The AI software turns raw experimental data into biological insight for researchers.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics trades on the NASDAQ, employs roughly 1,200 people, and is led by CEO Serge Saxonov.
10x Genomics in the AI buildout
10x Genomics sits in the AI Healthcare layer as a research tools maker whose software depends on AI. Its instruments generate huge biological datasets, and AI analysis in tools like Xenium and Cell Ranger is what makes those datasets useful. That said, the company's results track life science research budgets and instrument demand, with AI as an enabling feature rather than the driver. Supercycle scores its AI exposure at 12 out of 100.
TXG is tracked in AI Healthcare, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
TXG trades at $75.62, 95% of the way up its 52-week range of $11.34 to $79.10.
Market cap
Market capitalization is $2.20B, with an AI Exposure Score of 12 out of 100.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does 10x Genomics do?
10x Genomics sells single-cell and spatial biology instruments and consumables to researchers. Its platforms, including Chromium, Visium, and Xenium, help scientists study complex biological systems, with AI powering the analysis software.
How is 10x Genomics exposed to AI?
Lightly. Supercycle scores it 12 out of 100. AI is central to its analysis software, but revenue tracks life science tools demand and instrument placements, so AI is an enabling feature rather than the growth driver.
What are 10x Genomics' main products?
Chromium for single-cell analysis, Visium for spatial biology, Xenium with AI-driven analysis, and the Cell Ranger software pipeline. Instruments generate the data and the AI software interprets it for researchers.
Where is 10x Genomics headquartered and who leads it?
10x Genomics is headquartered in Pleasanton, California, and led by CEO Serge Saxonov. The company was founded in 2012, trades on the NASDAQ, and employs roughly 1,200 people.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.